| P50 | author | Sagnik Bhattacharyya | Q43272523 |
| | Cathy Davies | Q57615034 |
| P2093 | author name string | Michael Brammer | |
| | Jesus Perez | |
| | Philip McGuire | |
| | Robin M Murray | |
| | Paul Allen | |
| | Robin Wilson | |
| | Matthijs G Bossong | |
| | Elizabeth Appiah-Kusi | |
| | Grace Blest-Hopley | |
| P2860 | cites work | Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology | Q24602238 |
| | Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | Q24607361 |
| | Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients | Q24611774 |
| | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 |
| | Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia | Q24646206 |
| | Human cannabinoid pharmacokinetics | Q24652736 |
| | The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 |
| | Translating the MAM model of psychosis to humans | Q26860217 |
| | Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide | Q28362078 |
| | The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis | Q30047193 |
| | Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective. | Q30371792 |
| | Corticolimbic dysfunction during facial and prosodic emotional recognition in first-episode psychosis patients and individuals at ultra-high risk. | Q30372428 |
| | Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis | Q30450082 |
| | Adaptive analysis of fMRI data | Q30814069 |
| | Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life | Q33658933 |
| | Emotional perception: meta-analyses of face and natural scene processing | Q33720184 |
| | Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report | Q34137084 |
| | Effects of cannabidiol (CBD) on regional cerebral blood flow | Q34272906 |
| | Dissociable correlates of recollection and familiarity within the medial temporal lobes | Q34276428 |
| | A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation | Q34282923 |
| | Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment | Q34304341 |
| | Agonistic properties of cannabidiol at 5-HT1a receptors | Q34463976 |
| | Cannabidiol as a Potential Treatment for Anxiety Disorders | Q34492624 |
| | Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers | Q34639448 |
| | Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing | Q34915736 |
| | Cannabinoid modulation of functional connectivity within regions processing attentional salience | Q35420974 |
| | Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users | Q35431094 |
| | The relevance of behavioural measures for functional-imaging studies of cognition | Q35621341 |
| | Functional neuroimaging abnormalities in youth with psychosis spectrum symptoms | Q36089987 |
| | Neural correlates of aberrant emotional salience predict psychotic symptoms and global functioning in high-risk and first-episode psychosis | Q36111457 |
| | Emotion recognition in individuals at clinical high-risk for schizophrenia. | Q36244988 |
| | Repetition suppression of faces is modulated by emotion | Q36449166 |
| | Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity | Q36546326 |
| | Cannabinoid Modulation of Frontolimbic Activation and Connectivity During Volitional Regulation of Negative Affect | Q36906687 |
| | Cannabinoid modulation of amygdala reactivity to social signals of threat in humans | Q37132683 |
| | Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis | Q37228333 |
| | Dopamine release during human emotional processing | Q37340218 |
| | The privileged status of emotion in the brain | Q37483830 |
| | Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver | Q37665156 |
| | The Hippocampal Formation in Schizophrenia | Q37784600 |
| | Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults | Q38598495 |
| | Psychobiology of threat appraisal in the context of psychotic experiences: a selective review | Q38600811 |
| | Human Laboratory Studies on Cannabinoids and Psychosis. | Q38771523 |
| | Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor | Q38848638 |
| | Does cannabidiol have a role in the treatment of schizophrenia? | Q38884935 |
| | Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders | Q39166556 |
| | Misattribution of facial expressions of emotion in adolescents at increased risk of psychosis: the role of inhibitory control. | Q39869025 |
| | Social cognitive functioning in prodromal psychosis: A meta-analysis. | Q41273613 |
| | Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol | Q41437989 |
| | Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells | Q42488767 |
| | Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol | Q43272467 |
| | Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition | Q43970643 |
| | A preferential increase in the extrastriate response to signals of danger | Q44568880 |
| | Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis | Q46059613 |
| | The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning | Q46066974 |
| | Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis | Q46762892 |
| | The endocannabinoid system in guarding against fear, anxiety and stress | Q47618301 |
| | Facial emotion perception differs in young persons at genetic and clinical high-risk for psychosis | Q47910490 |
| | The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol | Q47991298 |
| | Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain | Q48244662 |
| | Analysis of a large fMRI cohort: Statistical and methodological issues for group analyses | Q48303386 |
| | Neural responses to dynamic expressions of fear in schizophrenia. | Q48481912 |
| | Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing | Q48731793 |
| | Detecting activations in PET and fMRI: levels of inference and power | Q48832601 |
| | Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis | Q49126675 |
| | The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. | Q49551829 |
| | Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention | Q50132400 |
| | Exaggerated brain activation during emotion processing in unaffected siblings of patients with schizophrenia. | Q50631037 |
| | Increased neural response related to neutral faces in individuals at risk for psychosis. | Q50876145 |
| | Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. | Q50879968 |
| | Sustained activation of the hippocampus in response to fearful faces in schizophrenia. | Q50971006 |
| | Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. | Q52750107 |
| | Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. | Q55361260 |
| | Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age | Q57300019 |
| | Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis | Q57403237 |
| | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test | Q57476923 |
| | Generic brain activation mapping in functional magnetic resonance imaging: A nonparametric approach | Q57773872 |
| | Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity | Q60290296 |
| | Effects of ipsapirone and cannabidiol on human experimental anxiety | Q83364228 |
| | Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind | Q90057471 |
| | Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis | Q91268421 |
| | Cannabidiol as a potential treatment for psychosis | Q91333459 |
| | Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders | Q91583578 |
| | Striatum-related functional activation during reward- versus punishment-based learning in psychosis risk | Q91610778 |
| | Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis | Q92506685 |
| | Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis | Q92796981 |
| | Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis | Q93023762 |
| P433 | issue | 1 | |
| P921 | main subject | psychosis | Q170082 |
| P304 | page(s) | 311 | |
| P577 | publication date | 2020-09-13 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis | |
| P478 | volume | 10 | |